US equities |
SPCX $167.59 ▲+5.43% NVDA $236.72 ▲+1.19% MU $1,067.94 ▼-0.65% TSLA $379.34 ▲+2.36% MSFT $526.48 ▲+1.73% SNDK $1,711.50 ▼-0.49% INTC $117.00 ▼-1.95% META $744.54 ▲+2.26%
FinancialContent

Articles published by Septerna, Inc.

News headline image
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna to Participate in Upcoming Investor Conferences
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting
From Septerna, Inc.
Via Business Wire
Tickers SEPN
News headline image
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna to Present at Bank of America Securities Health Care Conference
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna to Present at TD Cowen 46th Annual Health Care Conference
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna to Participate in 8th Annual Evercore Healthcare Conference
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna to Participate in Upcoming Investor Conferences
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna to Participate in Upcoming Investor Conferences
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna to Present at Jefferies Global Healthcare Conference
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna to Present at TD Cowen 45th Annual Health Care Conference
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN
News headline image
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Septerna, Inc.
Via GlobeNewswire
Tickers SEPN